Dr. Tsontcho Ianchulev

Breaking News · ASCRS 2026

Kelman Innovator
Lecture

Selected to deliver the prestigious Kelman Innovator Keynote at the ASCRS 2026 Congress.

LEARN MORE

Patients Treated

Peer-Review Citations

Issued Patents

FDA-Approved Products

Breaking News

On April 12th, 2026 at the ASCRS Congress Dr. Ianchulev received the Kelman Innovation award and delivered the Keynote lecture "Innovation: It takes a tribe!" at which he unveiled 4 new stealth technologies

Read the EyeWorld Coverage of Dr. Ianchulev's Lecture →

Op-Ed: "Where There Is No Sunshine [Act]" — on the Corcoran Consulting Group and the reimbursement-consultant disclosure gap →Medium

Portfolio

Innovations

Known as one of the most prolific ophthalmic inventors and entrepreneurs, Dr. Ianchulev has been at the forefront of ophthalmic innovation with many FDA-approved medical products.

Play

Ora

Wavered, Inc.

Acquired by Novartis, Inc.

Dr. Ianchulev invented intraoperative aberrometry - the first intra-operative biometry device for surgical intervention in ophthalmology. The ORA system uses infrared laser aberrometry for high-precision cataract surgery. It has been used in more than 3 million cataract surgeries worldwide.

Play

miLOOP

Iantech, Inc.

Acquired by Zeiss, Inc.

Dr. Ianchulev is the inventor of the miLOOP and founder of Iantech, Inc. miLOOP® is a memory-shaped, super-elastic nitinol fragmentation device for micro-interventional cataract surgery.

Play

Optejet

Eyenovia, Inc

IPO

Dr. Ianchulev led the development of the first FDA-approved pipette-free topical ophthalmic delivery system as well as the first smart, micro-dosing and horizontal-delivery technology in eye care.

Play

miCOR

Iantech, Inc.

Acquired by Zeiss, Inc.

Dr. Ianchulev founded Iantech Inc. in 2014 to create a first-in-class micro-interventional platform for subsonic, cavitation-free lensectomy and cataract surgery.

Play

CycloPen

Iantrek, Inc.

Private, Venture-backed

Dr. Ianchulev is the founder of Iantrek, Inc. and the inventor of the CycloPen supraciliary micro-interventional technology for glaucoma surgery, which received FDA approval in 2021.

Play

C.Rex

Iantrek, Inc.

Private, Venture-backed

Dr. Ianchulev is the founder of Iantrek, Inc. and the inventor of the C-Rex gonio-interventional technology for glaucoma surgery, which received FDA approval in 2021.

Macustat & Peristat

RemoniHealth, Inc

Private

More than 20 years ago, Dr. Ianchulev developed the first 100% virtual diagnostic devices (Peristat, Macustat) in eye care for remote vision testing and diagnosis of retinal and optic nerve diseases.

Play

RemoniHealth

RemoniHealth, Inc

Private

Dr. Ianchulev co-founded RemoniHealth, Inc - the first vision-as-a-service (VaaS) platform for remote patient monitoring and remote care management.

Play

AlloFlo Biostent

Iantrek, Inc.

Private, venture-backed

The AlloStent is the first bio-stent made entirely of biological material with no implantable hardware. It is used in the interventional treatment of glaucoma.

Play

CyPASS

Transcend Medical, Inc.

Acquired By Novartis

The first suprachoroidal MIGS stent to receive FDA approval. Used in thousands of patients worldwide.

Play

Preceyes Robotics

Preceyes, Inc.

Acquired by Zeiss, Inc.

As a key clinical collaborator and founding board member of Preceyes Robotics, Inc., Dr. Ianchulev's pioneering work lead to the first introduction of a clinical robotic system to the US in 2020.

Lucentis

Genentech, Inc

While at Genentech, Dr. Ianchulev lead the clinical research for Lucentis and the initial clinical efforts for one of the first bi-specific antibodies Vabyssmo.

Propionic Aciduria Optic Neuropathy

In 2002, Dr. Ianchulev was the first to describe the syndrome of propionic aciduria and optic neuropathy in children.

Office Based Cataract Surgery

With his seminal population health research on office based eye surgery and his 2016 publication of 21,000 cases, Dr. Ianchulev pioneered a new surgical paradigm with tremendous efficiency and cost-savings.

AEYE Health

AEYE Health, Inc.

FDA-Approved

Dr. Ianchulev is leading the way in AI and oculomics with two FDA approved systems for autonomous diabetic retinopathy screening

Dropmate

Dropmate Medical, Inc.

Private

The new paradigm of light-based point-of-care High Level Disinfection (HLD) www.dropmatemed.com

Play

AlloSpan

Iantrek, Inc.

Private, venture-backed

A novel MIGS (micro-invasive glaucoma surgery) technology platform for the interventional treatment of glaucoma. The first 100% biologic expandable stent in medicine.

BioGo

Sofia Biologics, Inc.

Private

A next-generation dry eye technology platform developing novel biological therapeutics for ocular surface disease.

STEALTH

miDOC

tap to unwrap

miDOC

Stealth

A high-precision biometry platform for advanced glaucoma diagnostics and surgical planning.

STEALTH

Aria

tap to unwrap

Aria

Stealth

An artificial intelligence platform for agentic patient empowerment.

STEALTH

FAI.bo

tap to unwrap

FAI.bo

Stealth

An AI-powered platform applying cutting-edge machine learning for rapid Forecasting, Analytics and Insights and Enhanced Business Outcomes (FAI.bo)

STEALTH

Replif.ai

tap to unwrap

Replif.ai

Stealth

Advanced AI System for Agentic Rep Amplification and Intelligent Client Engagement.

Expertise

Eye Surgeon

Dr. Ianchulev is a pioneering inventor in the field of eye surgery. He is responsible for groundbreaking surgical innovations such as high-precision, infrared laser-guided cataract surgery with intra-operative aberrometry, the first micro-interventional systems for cataract surgery with the miLOOP and miCOR technologies, the first supraciliary micro-stent for glaucoma, and the first Nitinol super-elastic filament technology for cataract and glaucoma interventions.

Dr. Ianchulev has also pioneered an entire category of bio-interventional ophthalmic surgery with the first implantable biologic micro-stent made of hardware-free, 100% allogeneic bio-tissue material.

Dr. Ianchulev received both his medical degree (MD) and a Master of Public Health (MPH) degree from Harvard University and completed his specialty training at the Doheny Eye Institute, University of Southern California. He is currently a Professor of Ophthalmology at New York Eye and Ear of Mount Sinai where he also directs the program for technology and innovation.

BOOK APPOINTMENT

Global Impact

Humanitarian

Dr. Ianchulev has led many sight-saving humanitarian missions in Africa and Latin America. He has donated his technologies and surgical talent for global outreach in the fight against cataract and glaucoma blindness.

Research

Academic

As a Professor of Ophthalmology, Dr. Ianchulev is recognized for his accomplishments and work in teaching and research. His innovative research has led to patents, licenses, and commercial products and has been cited by more than 4,000 peer-reviewed publications.

SEE PUBLICATIONS

1 / 4

Artwork